专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO02098457A3 RECOMBINANT RHABDOVIRUSES AS LIVE-VIRAL VACCINES FOR IMMUNODEFICIENCY VIRUSES 审中-公开
标题翻译：作为免疫缺陷病毒的真菌病毒的重组病毒血红蛋白
公开(公告)号：WO02098457A3
公开(公告)日：2003-04-24
申请号：PCT/US0200295
申请日：2002-01-08
申请人： UNIV JEFFERSON , SCHNELL MATTHIAS J , POMERANTZ ROGER J
发明人： SCHNELL MATTHIAS J , POMERANTZ ROGER J
IPC分类号： C07K14/145 , C07K14/16 , C12N15/86
CPC分类号： C12N15/86 , A61K2039/525 , C07K14/005 , C12N2740/16122 , C12N2760/20022 , C12N2760/20043 , C12N2760/20045 , C12N2810/6081
摘要： This invention provides recombinant, replication-competent Rhabdovirus vaccine strain-based expression vectors for expressing heterologous viral antigenic polypeptides such as immunodeficiency virus envelope proteins or subparts thereof. An additional transcription stop/start unit within the Rhabdovirus genome is inserted to express the heterologouos antigenic polypeptides. The HIV-1 gp 160 protein is stably and functionally expressed, as indicated by fusion of human T cell-lines after infection with the recombinant RVs. Inoculation of mice with the recombinant Rabies viruses expressing HIV-1 gp160 induces a strong humoral response directed against the HIV-1 envelope protein after a single boost with an isolated recombinant HIV-1 gp120 protein. Moreover, high neutralization titers, Up to 1:800, against HIV-1 are detected in the mouse sera. The present invention also shows that a single vaccination with recombinant RV expressing HIV-1 envelope protein elicits a strong, long-lasting CTL response specific against HIV-1 proteins, such as the envelope protein of different HIV-1 strains. These recombinant viral vectors expressing viral antigenic polypeptides provide useful and effective pharmaceutical compositions for the generation of viral specific immune responses.
摘要翻译：本发明提供用于表达异源病毒抗原性多肽（例如免疫缺陷病毒包膜蛋白或其子部分）的重组，基于复制能力的基于弹状病毒基因毒株的表达载体。插入Rhabdovirus基因组内的另外的转录停止/起始单位以表达异源抗原多肽。 HIV-1 gp 160蛋白质是稳定和功能表达的，如通过重组RV感染后的人T细胞系的融合所表明的。用重组的表达HIV-1 gp160的狂犬病病毒接种小鼠，用分离的重组HIV-1 gp120蛋白单次加强后，诱导针对HIV-1包膜蛋白的强烈体液应答。此外，在小鼠血清中检测到针对HIV-1的高中和滴度，高达1：800。本发明还显示用重组RV表达HIV-1包膜蛋白的单次疫苗接种引起针对HIV-1蛋白（例如不同HIV-1毒株的包膜蛋白）特异性的强烈的持久的CTL反应。表达病毒抗原多肽的这些重组病毒载体提供用于产生病毒特异性免疫应答的有用和有效的药物组合物。

2. 发明申请

WO2002098457A2 RECOMBINANT RHABDOVIRUSES AS LIVE-VIRAL VACCINES FOR IMMUNODEFICIENCY VIRUSES 审中-公开
标题翻译：作为免疫缺陷病毒的真菌病毒的重组病毒血红蛋白
公开(公告)号：WO2002098457A2
公开(公告)日：2002-12-12
申请号：PCT/US2002/000295
申请日：2002-01-08
申请人： THOMAS JEFFERSON UNIVERSITY , POMERANTZ, Roger, J. , SCHNELL, Matthias, J.
发明人： POMERANTZ, Roger, J. , SCHNELL, Matthias, J.
IPC分类号： A61K39/12
CPC分类号： C12N15/86 , A61K2039/525 , C07K14/005 , C12N2740/16122 , C12N2760/20022 , C12N2760/20043 , C12N2760/20045 , C12N2810/6081
摘要： This invention provides recombinant, replication-competent Rhabdovirus vaccine strain-based expression vectors for expressing heterologous viral antigenic polypeptides such as immunodeficiency virus envelope proteins or subparts thereof. An additional transcription stop/start unit within the Rhabdovirus genome is inserted to express the heterologouos antigenic polypeptides. The HIV-1 gp 160 protein is stably and functionally expressed, as indicated by fusion of human T cell-lines after infection with the recombinant RVs. Inoculation of mice with the recombinant Rabies viruses expressing HIV-1 gp160 induces a strong humoral response directed against the HIV-1 envelope protein after a single boost with an isolated recombinant HIV-1 gp120 protein. Moreover, high neutralization titers, Up to 1:800, against HIV-1 are detected in the mouse sera. The present invention also shows that a single vaccination with recombinant RV expressing HIV-1 envelope protein elicits a strong, long-lasting CTL response specific against HIV-1 proteins, such as the envelope protein of different HIV-1 strains. These recombinant viral vectors expressing viral antigenic polypeptides provide useful and effective pharmaceutical compositions for the generation of viral specific immune responses.
摘要翻译：本发明提供用于表达异源病毒抗原性多肽（例如免疫缺陷病毒包膜蛋白或其子部分）的重组，基于复制能力的基于弹状病毒基因毒株的表达载体。插入Rhabdovirus基因组内的另外的转录停止/起始单位以表达异源抗原多肽。 HIV-1 gp 160蛋白质是稳定和功能表达的，如通过重组RV感染后的人T细胞系的融合所表明的。用重组的表达HIV-1 gp160的狂犬病病毒接种小鼠，用分离的重组HIV-1 gp120蛋白单次加强后，诱导针对HIV-1包膜蛋白的强烈体液应答。此外，在小鼠血清中检测到针对HIV-1的高中和滴度，高达1：800。本发明还显示用重组RV表达HIV-1包膜蛋白的单次疫苗接种引起针对HIV-1蛋白（例如不同HIV-1毒株的包膜蛋白）特异性的强烈的持久的CTL反应。表达病毒抗原多肽的这些重组病毒载体提供用于产生病毒特异性免疫应答的有用和有效的药物组合物。

3. 发明申请

WO2009016433A2 ONCOLYTIC RHABDOVIRUS 审中-公开
公开(公告)号：WO2009016433A2
公开(公告)日：2009-02-05
申请号：PCT/IB2007004701
申请日：2007-09-17
申请人： OTTAWA HEALTH RESEARCH INST , STOJDL DAVID , BROWN CHRISTOPHER , BELL JOHN
发明人： STOJDL DAVID , BROWN CHRISTOPHER , BELL JOHN
IPC分类号： A61K35/766
CPC分类号： A61K35/766 , A61K35/761 , A61K35/763 , A61K35/768 , A61K45/06 , C12N7/00 , C12N2760/20032 , C12N2760/20045 , C12N2760/20221 , C12N2760/20222 , C12N2760/20232 , C12N2760/20271 , C12N2810/6081
摘要： Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdo viruses possess tumor cell killing properties in vitro and in vivo.
摘要翻译：本发明的实施方案包括与非VSV弹状病毒相关的组合物和方法及其作为抗癌治疗剂的用途。这种狂犬病毒在体外和体内具有肿瘤细胞杀伤性质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式